Interferon regulatory factor 1 regulation of oligodendrocyte injury and inflammatory demyelination

Reviews in the Neurosciences

Volumn 23, Issue 2, 2012, Pages 145-152

  Loda, Eileah ^a   Balabanov, Roumen ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Caspase 1; central nervous system (CNS) inflammation; demyelination; glial cells; interferon regulatory factor 1; IRF 1; multiple sclerosis; oligodendrocytes

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P35; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNITY; CELL DEATH; CELL DIFFERENTIATION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; DEMYELINATION; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; GENE SILENCING; HUMAN; IMMUNIZATION; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TH2 CELL;

ANIMALS; CASPASE 1; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA; SIGNAL TRANSDUCTION;

EID: 84861087063     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2011-068     Document Type: Review

References (56)

1. Agresti, C., Bernardo, A., Del Russo, N., Marziali, G., Battistini, A., Aloisi, F., Levi, G., and Coccia, E. (1998). Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-βand TNF-βin oligodendrocytes. Eur. J. Neurosci. 10 , 2975-2983.
2. Baerwald, K., Corbin, J., and Popko, B. (2000). Major histocompatibility complex heavy chain accumulation in the endoplasmic reticulum of oligodendrocytes results in myelin abnormalities. J. Neurosci. Res. 15 , 160-169.
3. Balabanov, R., Stand, K., Kemper, A., Lee, J., and Popko, B. (2006). Suppressor of cytokine signaling 1 expression protects oligodendrocytes from the deleterious effects of interferon-β. J. Neurosci. 26 , 5143-5152.
4. Balabanov, R., Strand, K., Goswami, R., McMahon, E., Begolka, W., Miller, S., and Popko, B. (2007). Interferon-β-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J. Neurosci. 27 , 2013-2024.
5. Barnett, M. and Prineas, J. (2004). Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55 , 458-468.
6. Bergsbaken, T., Fink, L., and Cookson, T. (2009). Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 7 , 99-109.
7. Bouker, K., Skaar, T., Riggis, R., Harburger, D., Fernandez, D., Zwart, A., Wand, A., and Clark, R. (2005). Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 26 , 1527-1535.
8. Buch, T., Uthoff-Hachenberg, C., and Waisman, A. (2003). Protection from autoimmune brain inflammation in mice lacking IFNregulatory factor-1 is associated with Th2-type cytokines. Int. Immunol. 15 , 855-856.
9. Butzkueven, H., Zhang, J., Hanninen, M., Hochrein, H., Chionh, F., Shipham, K., Emery, B., Turnley, A., Petratos, S., Ernst, M., et al. (2002). LIF receptor signaling limits immune mediated demyelination by enhancing oligodendrocyte survival. Nat. Med. 8 , 613-619.
10. Calabresi, P., Tranquill, L., McFarland, H., and Cowan, E. (1998). Cytokine gene expression in cells derived from CSF of multiple sclerosis patients. J. Neuroimmunol. 89 , 198-205.
11. Chew, L., King, W., Kennedy, A., and Gallo, V. (2005). Interferongamma inhibits cell cycle exit in differentiating oligodendrocyte progenitor cells. Glia 52 , 127-143.
12. Corbin, J., Kelly, D., Rath, E., Baerwald, K., Suzuki, K., and Popko, B. (1996). Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol. Cell. Neurosci. 7 , 354-370.
13. Feng, X., Petraglia, A., Chen, M., Byskosh, P., Boos, M., and Reder, A. (2002). Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J. Neuroimmunol. 129 , 205-215.
14. Fink, L. and Cookson, T. (2005). Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect. Immun. 73 , 1907-1916.
15. Fortunato, G., Calcagno, G., Bresciamorra, V., Salvatore, E., Filla, A., Capone, S., Liquori, R., Borelli, S., Gentile, L., Borelli, F., et al. (2008). Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J. Interferon Cytokine Res. 28 , 141-152.
16. Gobin, S., Mantagne, L., Van Zutphen, M., Van Der Valk, P., Van Den Elsen, P., and De Groot, C. (2001). Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia 36 , 68-77.
17. Hafler, D. (2004). Multiple sclerosis. J. Clin. Invest. 113 , 778-794.
18. Hirsch, R., Panitch, H., and Johnson, K. (1985). Lymphocytes from multiple sclerosis produce elevated levels of βinterferon in vitro . J. Clin. Immunol. 5 , 386-389.
19. Hisahara, S., Araki, T., Sugiyama, F., Yagami, K., Suzuki, M., Abe, K., Yamamura, K., Miyazaki, J., Momoi, T., Satura, T., et al. (2000). Targeted expression of baculovirus p35 caspase inhibitor in oligodendrocytes protects mice against autoimmune-mediated demyelination. EMBO J. 19 , 341-348.
20. Höftberger, R., Aboul-Enein, F., Brueck, W., Lucchinetti, C., Rodriguez, M., Schmidbauer, M., Jellinger, K., and Lassmann, H. (2004). Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 14 , 43-50.
21. Horiuchi, M., Itoh, A., Pleasure, D., and Itoh, T. (2006). MEK-ERK signaling is involved in interferon-gamma-induced death of oligodendroglial progenitor cells. J. Biol. Chem. 281 , 2095-2106.
22. Horiuchi, M., Itoh, A., Pleasure, D., Ozato, K., and Itoh, T. (2011). Cooperative contribution of interferon regulatory factor 1 (IRF-1) and IRF-8 to interferon-β-medicated cytotoxic effect on oligodendrocyte progenitor cells. J. Neuroinflamm. 8 , 8.
23. Hovelmeyer, N., Hao, Z., Kranidioti, K., Kassiotis, G., Buch, T., Frommer, F., von Hoch, L., Kramer, D., Minichiello, L., Kollias, G., et al. (2005). Apoptosis of oligodendrocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis. J. Immunol. 175 , 5875-5884.
24. Kassmann, C., Lappe-Siefke, C., Baes, M., Brügger, B., Mildner, A., Werner, H., Natt, O., Michaelis, T., Prinz, M., Frahm, J., et al. (2007). Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat. Genet. 39 , 969-976.
25. Killestein, J., Rep, M., Barkof, F., Roos, M., Adler, H., van Lier, R., and Polman, C. (2001). Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells. J. Neuroimmunol. 118 , 286-294.
26. Lassmann, H. (2005). Multiple sclerosis pathology: evaluation of pathogenic concepts. Brain. Pathol. 15 , 217-222.
27. Lin, W., Harding, H., Ron, D., and Popko, B. (2005). Endoplasmic reticulum stress modulates the response of myelinating oligodendrocytes to the immune cytokine interferon-gamma. J. Cell. Biol. 169 , 603-612.
28. Linker, R., Maüer, M., Gaupp, S., Martini, R., Holtmann, L., Giess, R., Rieckmann, P., Lassmann, H., Toyka, K., Sendtner, M., et al. (2002). CNTF is a major protective factor in demyelinating CNS disease: a neuroprotective cytokine as modulator in neuroinflammation. Nat. Med. 8 , 620-624.
29. Lohoff, M. and Mak, T. (2005). Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat. Rev. Immunol. 5 , 125-135.
30. Lucchinetti, C., Brück, W., Parisi, J., Scheitauer, B., Rodriguez, M., and Lassmann, H. (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 , 707-717.
31. Marta, T., Anderson, A., Isaksson, M., Kä mpe, O., and Lobell, A. (2008). Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 38 , 565-575.
32. Martino, G., Franklin, R., Van Evercooren, A., Kerr, D., Stem Cells in Multiple Sclerosis (STEMS) Consensus Group (2010). Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat. Rev. Neurol. 6 , 247-255.
33. Matsuyama, T., Kimura, T., Kitagawa, M., Pfeffer, K., Kawakami, T., Watanabe, N., Kündig, T.M., Amakawa, R., Kishihara, K., and Wakeham, A. (1993). Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75 , 83-97.
34. McGuire, C., Volckaert, T., Wolke, U., Sze, M., de Rycke, R., Waisman, A., Prinz, M., Beyaert, R., Rasparakis, M., and van Loo, G. (2010). Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination. J. Immunol. 185 , 7646-7653.
35. Mi, S., Hu, B., Hahm, K., Luo, Y., Kam Hui, ES., Yuan, Q., Wong, W., Wang, L., Su, H., Chu, T., et al. (2007). LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 13 , 1228-1233.
36. Ming, X., Li, W., Maeda, Y., Cook, S., Chapin, J., Husar, W., and Dowling, P. (2002). Caspase 1 expression in multiple sclerosis plaques and cultured glial cells. J. Neurol. Sci. 197 , 9-18.
37. Moldovan, I., Rudick, R., Cotleur, A., Born, S., Lee, J., Karafa, M., and Pelfrey, C. (2003). Interferon βresponses to myelin peptides in multiple sclerosis correlate with new clinical measure of disease progression. J. Neuroimmunol. 141 , 132-140.
38. Noseworthy, J., Lucchinetti, C., Rodriguez, M., and Weinshenker, B. (2000). Multiple sclerosis. N. Engl. J. Med. 343 , 938-952.
39. Panitch, N., Hirsch, R., Haley, A., and Johnson, K. (1987). Exacerbations of multiple sclerosis in patients treated with βinterferon. Lancet 1 , 893-895.
40. Pouly, S., Becher, B., Blain, M., and Antel, J. (2000). Interferon-βmodulates human oligodendrocyte susceptibility to Fas-mediated injury. J. Neuropathol. Exp. Neurol. 59 , 280-286.
41. Ren, Z., Wang, Y., Tao, D., Liebenson, D., Liggett, T., Goswami, R., Stefoski, D., and Balabanov, R. (2010). Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis. J. Neuroimmune Pharmacol. 5 , 260-265.
42. Ren, Z., Wang, Y., Tao, D., Liebenson, D., Liggett, T., Goswami, R., Stefoski, D., and Balabanov, R. (2011a). IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination. J. Neuroimmunol. 233 , 147-159.
43. Ren, Z., Wang, Y., Tao, D., Liebenson, D., Liggett, T., Goswami, R., Stefoski, D., and Balabanov, R. (2011b). Overexpression of the dominant negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis. J. Neurosci. 83 , 8329-8341.
44. Skurkovich, S., Boiko, A., Beliaeva, I., Buglak, I., Alekseeva, T., Smirnova, T., Kulakova, O., Tchechonin, V., Gurova, O., Deomina, T., et al. (2001). Randomized study of antibodies to IFN-βand TNF-βin secondary progressive multiple sclerosis. Mult. Scler. 7 , 277-284.
45. Steinman, L. (1996). Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 185 , 299-302.
46. Steinman, L. (2001). Blockade of gamma interferon might be benefi-cial in MS. Mult. Scler. 7 , 275-276.
47. Steinman, L. and Zamvil, S. (2006). How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60 , 12-21.
48. Swanborg, R. (1988). Experimental allergic encephalomyelitis. Methods Enzymol. 140 , 1132-1138.
49. Tada, Y., Ho, A., Matsuyma, T., and Mak, T. (1997). Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J. Exp. Med. 185 , 231-238.
50. Tanner, D., Cherry, J., and Mayer-Pröschel, M. (2011). Oligodendrocyte progenitors reversibly exit the cell cycle and give rise to astrocytes in response to interferon-β. J. Neurosci. 31 , 6235-6246.
51. Torres, C., Aranguez, I., and Rubino, N. (1995). Expression of interferon-gamma receptor on murine oligodendrocytes and its regulation by cytokines and mitogens. Immunology 86 , 250-255.
52. Tompkins, S., Padilla, M., Dal Canto, J., Ting, J., Van Kaer, L., and Miller, S. (2002). De novo CNS processing of myelin antigen is required for the initiation of EAE. J. Immunol. 168 , 4173-4183.
53. Turnley, A., Miller, J., and Bartlett, P. (1991). Regulation of MHC molecules on MBP positive oligodendrocytes in mice by IFN-βand TNF-β. Neurosci. Lett. 123 , 45-48.
54. Vartanian, T., Li, Y., Zhao, M., and Stefansson, K. (1996). Interferon-β-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol. Med. 1 , 732-743.
55. Wang, Y., Ren, Z., Tao, D., Tilwalli, S., Goswami, R., and Balabanov, R. (2010). STAT1/IRF-1 signaling pathway mediates the injurious effect of interferon-gamma on oligodendrocyte progenitor cells. Glia 58 , 195-209.
56. Zeis, T., Graumann, U., Reynolds, R., and Schaeren-Wiemers, N. (2008). Normal-appearing white matter in multiple sclerosis is a subtle balance between inflammation and neuroprotection. Brain 131 , 288-303.